GlassScriptPhysician profile
Joni L Yamamoto
NPI 1528126679
$4,457.11
in general payments reported to CMS, 2019-2025
36 companies · $844 in 2025
The $844 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $452 · 2021: $401 · 2022: $744 · 2023: $809 · 2024: $685 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,338.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $646.31 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $494.38 | 2019-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $391.24 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $319.91 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.96 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $246.88 | 2019-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $227.24 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $197.17 | 2021-2025 | |
| Exact Sciences Corporation | $183.35 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $167.81 | 2019-2023 | |
| Abbott Laboratories | $145.48 | 2019-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $116.79 | 2022 | |
| Janssen Pharmaceuticals, INC | $115.41 | 2019-2021 | |
| Glaxosmithkline, LLC. | $111.70 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Xeris Pharmaceuticals, INC. | $111.26 | 2021-2025 | Gvoke Hypopen |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.98 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $59.88 | 2024 | Voquezna |
| Cranial Technologies, INC | $57.60 | 2021-2024 | Doc Band |
| Amarin Pharma, INC. | $55.41 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $53.58 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $45.60 | 2023 | Rexulti |
| Allergan, INC. | $42.75 | 2020 | |
| Merck Sharp & Dohme LLC | $34.67 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $33.97 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $30.49 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.36 | 2020-2021 | |
| Axsome Therapeutics, INC. | $25.59 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $19.77 | 2020 | |
| Daiichi Sankyo INC. | $17.89 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.52 | 2021 | |
| Shield Therapeutics INC | $15.94 | 2025 | |
| Eisai INC. | $12.39 | 2020 | |
| Dexcom, INC. | $12.31 | 2021 | |
| Almatica Pharma LLC | $12.14 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.84 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joni Yamamoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.